Business
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
Expands clinical expertise to support disciplined advancement of the PSX-001 programMELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide i
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"Expands clinical expertise to support disciplined advancement of the PSX-001 program","length":84,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD.","length":384,"tagName":"p"},{"type":"text","content":"The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board’s expertise across psychiatry, neurobiology, psychopharmacology, and clinical development, reinforcing the scientific rigor and strategic framework underpinning the PSX-001 program. Among its roles, the CAB will advise Incannex on clinical trial design, endpoint selection, regulatory engagement, and broader development strategy as PSX-001 advances.","length":596,"tagName":"p"},{"type":"text","content":"“The continued expansion of our Clinical Advisory Board reflects the increasing complexity and importance of the decisions ahead for the PSX-001 program,” stated Incannex Healthcare Chief Medical Officer Dr. Lou Barbato. “As we advance PSX-001, the perspectives of these additional leaders will help inform key clinical and regulatory decisions, support disciplined execution across development milestones, and strengthen the strategic foundation of the program. This deliberate approach to advisory oversight is designed to enhance decision-making, manage risk, and support long-term shareholder value.”","leng...